ClinicalTrials.gg
Active, not recruitingNCT06962956Updated Jun 3, 2025

Evaluating Gingivitis and Systemic Biomarkers

A Phase 1 interventional study of 0.76% Sodium Monofluorophosphate Dentifrice and 0.454% Stannous Fluoride Dentifrice in Gingivitis, sponsored by Procter and Gamble. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Procter and Gamble · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Planned enrollment
6th of 23
135 · median 115
Started
2025
with 2 others
Phase 1
Only one
of the 23
Registered
18th of 23
by date
Lead sponsor
9 of 23
Procter and Gamble

Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 1, and was the 18th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

This exploratory study will consist of two parts: Phase 1 (sample collection/screening) and Phase 2 (sample collection/product efficacy testing). The purpose of Phase 1 is to understand the association of gingivitis to systemic biomarkers and to screen subjects for Phase 2. The purpose of Phase 2 is to assess the causal effect of oral hygiene intervention on gingivitis and systemic biomarkers.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide and receive a signed copy of the informed consent form;
  • Be between 25 - 65 years of age;
  • Have at least 16 gradable teeth;
  • Have a minimum of (approximately) 30% of bleeding sites and no more than two teeth with pockets deeper than 5mm or deemed acceptable by the Investigator/Designee (unhealthy test subjects only);
  • Have less than or equal to 3 bleeding sites and with all pockets less than or equal to 3mm deep (healthy test subjects only);
  • Agree to fast 12 hours prior to any visit with a blood collection;
  • Agree to not perform any oral hygiene for at least 12 hours prior to any visit with dental exams, saliva collection, and plaque collections;
  • Agree to refrain from eating or drinking, using medicated lozenges, breaths mints, and chewing gum at least 4 hours prior to this study visit (exception allowed: small sips of water up until 45 minutes prior to their appointment) for any visit with plaque collections;
  • Agree to refrain from use of any non-study oral hygiene products after the Product Distribution visit;
  • Agree to continue their current oral hygiene products and habits until the Product Distribution visit;
  • Agree to delay any elective dentistry, including dental prophylaxis outside of the study protocol, until the completion of the study;
  • Agree to all study restrictions for the duration of the study (medicines/supplements/vaccines- see restricted list);
  • Agree not to participate in any other oral care studies for the duration of this study;
  • Agree to return for all scheduled visits and to follow all study procedures; and
  • Be in good general health, as determined by the Investigator/Designee based on a review of their health history.

Exclusion criteria

Exclusion Criteria:

  • Severe periodontal disease, including but not limited to purulent exudate, generalized mobility, and/or severe recession;
  • Active treatment for gingivitis, periodontitis, or caries;
  • Daily use of NSAID;
  • Having any of the following: fixed orthodontic appliances or attachments for aligner treatment, lower bonded retainers; removable partial dentures, peri/oral piercings, a pacemaker or other implanted device, unless deemed acceptable by the Investigator/Designee;
  • A condition requiring the need for antibiotic premedication prior to dental procedures;
  • Use of anti-inflammatory or anti-coagulant medications within 2 weeks of the Baseline visit, unless deemed acceptable by the Investigator/Designee;
  • Having had oral/gum surgery within the previous 2 months;
  • Smoking or vaping (regardless of content), use of smokeless tobacco, e-cigarettes, or nicotine patches);
  • Currently using recreational drugs;
  • Having been diagnosed with cardiovascular disease, diabetes (having an ≥ 7), rheumatoid arthritis, liver disease, IBS, Crohn's Disease, Chronic Kidney Disease, or any type of disease;
  • Having any gastrointestinal issues (e.g. diarrhea, vomiting) in the past week;
  • Use of statins or cholesterol lowering medication or supplements (e.g., Flax seeds, omega-3 fatty acids, Magnesium Oxide ≥250mg, Zyflamed, supplements containing berberine, golden thread, turmeric, CoQ10, or quercetin) for the duration of the study;
  • Use of antibiotics or having a dental prophylaxis in the last 4 weeks prior the baseline visit, unless deemed acceptable by the Investigator/Designee;
  • Receiving a flu shot or other vaccination in the last 4 weeks prior the baseline visit;
  • Inability to undergo any study procedures;
  • Currently undergoing treatment with GLP-1s antagonist;
  • Nursing, self-reported pregnancy or the intention of becoming pregnant any time during the course of this study; or
  • Having any condition or disease, as determined by the Investigator/Designee based on a review of the medical history which could be expected to interfere with examination procedures or with the subject's safe completion of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    Negative Control

    0.76% sodium monofluorophosphate

    Drug: 0.76% Sodium Monofluorophosphate Dentifrice

  • Active comparator
    Test

    0.454% stannous fluoride

    Drug: 0.454% Stannous Fluoride Dentifrice

  • Active comparator
    Positive Control

    0.454% stannous fluoride

    Drug: 0.454% Stannous Fluoride Dentifrice

Interventions

06

What researchers measure

Primary outcomes

  1. Number Bleeding Sites

    Total number of bleeding sites

    Time frame: 4 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.

Of 11 phase 1 interventional studies under Gingivitis, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 7. This study's planned 6 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Oct 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06962956
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Apr 30, 2025
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Jun 3, 2025

Study contacts

Salus Research
principal investigator · Salus Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion